GlassScriptPhysician profile
Clara Chow
NPI 1306379599
$34,718.98
in general payments reported to CMS, 2019-2025
19 companies · $19K in 2025
The $19K reported for 2025 was more than what 94% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,045 · 2024: $15K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Honoraria: $11K · Food and Beverage: $3,809 · Travel and Lodging: $3,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,465.00 |
| Honoraria | $11,120.00 |
| Food and Beverage | $3,808.84 |
| Travel and Lodging | $3,325.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $19,919.70 | 2024-2025 | Elevidys, Exondys 51 |
| Catalyst Pharmaceuticals, INC. | $10,723.86 | 2024-2025 | |
| Itf Therapeutics LLC | $1,555.78 | 2025 | |
| Ucb, INC. | $530.38 | 2023-2024 | Zilbrysq |
| Alexion Pharmaceuticals, INC. | $370.41 | 2023-2024 | Ultomiris, Soliris |
| Janssen Biotech, INC. | $328.75 | 2025 | |
| Biogen, INC. | $190.01 | 2024-2025 | Spinraza, Skyclarys |
| Grifols USA, LLC | $169.88 | 2023 | Gamunex-C |
| Genentech USA, INC. | $153.84 | 2023-2025 | Evrysdi |
| Grifols Shared Services North America, INC. | $129.28 | 2024 | Gamunex-C |
| Csl Behring | $126.59 | 2023 | Hizentra |
| Amgen INC. | $125.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.67 | 2023 | Hyqvia |
| Argenx US, INC. | $98.20 | 2024 | Vyvgart |
| Janssen Scientific Affairs, LLC | $59.95 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ns Pharma, INC. | $46.86 | 2024-2025 | Viltepso |
| Boston Scientific Corporation | $44.10 | 2023-2025 | General - Pain Management |
| Cycle Pharmaceuticals INC | $29.05 | 2025 | Ormalvi |
| Acadia Pharmaceuticals INC | $17.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.